Selincro, developed by Finland's Biotie Therapies, reduces "alcohol consumption by about 60%" or about a bottle of wine a day after six months, Danish drugmaker Lundbeck said.
With the go-ahead from the European Commission, Lundbeck, which will manufacture the medication, said it expects to launch Selincro by the middle of this year.
Selincro is mainly aimed at reducing alcohol dependence in adults who drink heavily consuming up to six drinks a day but who do not suffer from withdrawal symptoms or need detoxification.
"Selincro is thought to reduce the reinforcing effects of alcohol, and thereby reduces the urge to drink alcohol," Lundbeck said.
Lundbeck said excessive alcohol consumption is a world-wide problem, especially in Europe where it said more than 14m people are dependent on alcohol.
Source: AFP via I-Net Bridge
For more than two decades, I-Net Bridge has been one of South Africa’s preferred electronic providers of innovative solutions, data of the highest calibre, reliable platforms and excellent supporting systems. Our products include workstations, web applications and data feeds packaged with in-depth news and powerful analytical tools empowering clients to make meaningful decisions.
We pride ourselves on our wide variety of in-house skills, encompassing multiple platforms and applications. These skills enable us to not only function as a first class facility, but also design, implement and support all our client needs at a level that confirms I-Net Bridge a leader in its field.
Go to: http://www.inet.co.za
